Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chart: Obesity: Three New Drug Candidates Promise A New Dawn

Executive Summary

Arena is positioning its pending anti-obesity NME lorcaserin as the cure for the obesity market hangover induced by the troublesome side effect profiles associated with earlier Rx weight loss products.

You may also be interested in...

Orexigen Insists Revised Contrave Data Should Not Affect Timing Of NDA

FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.

Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts